Phase I Dose-Escalation Bioavailability Study of Oral Triapine in Combination With Concurrent Chemoradiation for Locally Advanced Cervical Cancer (LACC) and Vulvar Cancer

Trial Profile

Phase I Dose-Escalation Bioavailability Study of Oral Triapine in Combination With Concurrent Chemoradiation for Locally Advanced Cervical Cancer (LACC) and Vulvar Cancer

Suspended
Phase of Trial: Phase I

Latest Information Update: 16 Aug 2017

At a glance

  • Drugs OCX 191 (Primary) ; Cisplatin
  • Indications Adenocarcinoma; Cervical cancer; Vulvar intraepithelial neoplasia
  • Focus Adverse reactions
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 27 Oct 2016 Status changed from recruiting to suspended due to drug supply issues.
    • 30 Jun 2016 Planned number of patients changed from 48 to 64.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top